Bionano Announces Software Marketing Agreement with Revvity for Newborn Sequencing Research
Summary
Revvity’s end-to-end workflow includes DNA extraction of dried blood spot samples, sample quality control and quantification, automated library preparation, sequencing, using systems from Element Biosciences or Illumina, a hybridization-based NGS panel designed to identify variants in over 390 genes that are relevant for newborn sequencing research, cloud-based data management, and analysis with VIA software. Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of geopolitical and macroeconomic developments, such as recent and potential future bank failures, supply chain disruptions, global pandemics, inflation and the ongoing conflicts between Ukraine and Russian and Israel and Hamas, on our business and the global economy; general market conditions; the failure of VIA software to be useful for NGS and newborn sequencing research applications; the failure of VIA software to assess CNVs in NGS workflows for research applications; the failure of VIA software to enhance the report interpretation capabilities of Revvity’s workflow for research applications including newborn sequencing research applications; changes in our strategic and commercial plans or the strategic or commercial plans of our partner; our need and ability to obtain sufficient financing to fund our strategic plans and commercialization efforts, our ability to effectively manage our uses of cash, and our ability to continue as a “going concern”; the ability of institutions to obtain funding to support adoption or continued use of our technologies and the solutions offered by our partner; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2023 and in other filings subsequently made by us with the Securities and Exchange Commission. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.